Old Bridge Flexi Cap Fund
Direct · GrowthAI Summary
Old Bridge Flexi Cap Fund has delivered positive returns against a weak NIFTY 50 across all tracked periods, with a 1Y fund CAGR of 2.7% versus the benchmark's -6.92%, generating a 1Y alpha of 4.07%. However, over longer horizons the alpha turns negative, with 5Y alpha at -1.32% and 15Y alpha at -2.23%, indicating benchmark outperformance only in the recent weak market. SIP XIRR data is unavailable, so direct comparison to the category average SIP XIRR of 9.47% (1Y) and 16.07% (5Y) cannot be made like-for-like.
The fund exhibits a low beta of 0.59 versus NIFTY 50, capturing only 64.18% of market upside but a lower 53.44% of downside, which explains its cushioning in falling markets. Risk metrics show a very shallow maximum drawdown of just -0.12% with a 67-day duration yet no recorded recovery and only one drawdown event exceeding 10%, suggesting unusually low volatility in the observed period. While active protection in down markets is evident, the muted upside capture limits participation in strong rallies.
The top 10 holdings across 31 total positions are tightly clustered between 3.14% and 4.01% of NAV, led by Shriram Finance (4.01%) and Hindalco Industries (3.99%), showing no single stock dependency. Sector exposure is well spread, with pharmaceuticals the largest at 13.9% followed by finance at 6.8%, and meaningful weightages in agriculture, construction, and banking. The 31-stock portfolio of mid-sized positions indicates a deliberately diversified, bottom-up stock-picking approach.
The fund's defensive profile distinguishes it within the flexi cap category, notably outperforming the benchmark in 1Y while lagging it modestly over longer windows. Positive 1Y calendar year return of 2.7% in a period when NIFTY 50 contracted suggests strong relative performance against category peers in difficult markets. Without XIRR data, consistency versus the category average SIP XIRR trends cannot be fully verified.
This fund suits conservative equity investors seeking lower volatility exposure with downside protection, given its beta of 0.59 and favorable downside capture of 53.44%. A long-term horizon of 5-7 years or more is appropriate, as longer-period alpha remains negative and the fund's value emerges primarily in weak market phases. Investors comfortable with restrained upside in bull markets and wanting a diversifier within a broader equity portfolio would find it most suitable.
- Strong downside protection with downside capture of 53.44% and beta of 0.59 versus NIFTY 50
- Positive 1Y alpha of 4.07% with fund CAGR of 2.7% against benchmark's -6.92%
- Well-diversified portfolio of 31 stocks with no single stock above 4.01% of NAV
- Negative alpha over longer horizons, worsening from -0.41% at 3Y to -2.23% at 15Y
- Low upside capture of 64.18% limits participation in market rallies, and SIP XIRR data is unavailable for category comparison
Generated on 05-11-2026, 3:02 AM. Verify before investing.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
Not enough data to compute SIP returns.
Not enough data to compute rolling returns.
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +5.48 | 0.59 | 64.9% | 53.4% | 8.8% | 1.1% |
| 3 Years | -0.04 | 0.59 | 64.9% | 53.4% | 2.9% | 0.3% |
| 5 Years | -1.10 | 0.59 | 64.9% | 53.4% | 1.7% | 0.2% |
| 7 Years | -1.56 | 0.59 | 64.9% | 53.4% | 1.2% | 0.1% |
| 10 Years | -1.89 | 0.59 | 64.9% | 53.4% | 0.8% | 0.1% |
| 12 Years | -2.03 | 0.59 | 64.9% | 53.4% | 0.7% | 0.1% |
| 15 Years | -2.16 | 0.59 | 64.9% | 53.4% | 0.6% | 0.1% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Shriram Finance Limited | 4.01% |
| 2 | Hindalco Industries Limited | 3.99% |
| 3 | Gujarat Ambuja Exports Limited | 3.76% |
| 4 | Star Health And Allied Insurance Company Limited | 3.60% |
| 5 | InterGlobe Aviation Limited | 3.40% |
| 6 | Balkrishna Industries Limited | 3.39% |
| 7 | NCC Limited | 3.33% |
| 8 | Aurobindo Pharma Limited | 3.27% |
| 9 | Redington Limited | 3.20% |
| 10 | Zydus Lifesciences Limited | 3.14% |